K Hertogs

Summary

Country: Belgium

Publications

  1. pmc A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
    K Hertogs
    VIRCO, Central Virological Laboratory, Edegem, Belgium
    Antimicrob Agents Chemother 42:269-76. 1998
  2. pmc A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
    K Hertogs
    Virco NV, Mechelen, Belgium
    Antimicrob Agents Chemother 44:568-73. 2000
  3. ncbi request reprint Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples
    K Hertogs
    Virco NV, Mechelen, Belgium
    AIDS 14:1203-10. 2000
  4. pmc The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence
    H Van Marck
    Tibotec BVBA, Mechelen, Belgium
    J Virol 83:9512-20. 2009

Detail Information

Publications4

  1. pmc A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
    K Hertogs
    VIRCO, Central Virological Laboratory, Edegem, Belgium
    Antimicrob Agents Chemother 42:269-76. 1998
    ..This assay system facilitates the rapid large-scale phenotypic resistance determinations for all RT and PR inhibitors in one standardized assay...
  2. pmc A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
    K Hertogs
    Virco NV, Mechelen, Belgium
    Antimicrob Agents Chemother 44:568-73. 2000
    ....
  3. ncbi request reprint Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples
    K Hertogs
    Virco NV, Mechelen, Belgium
    AIDS 14:1203-10. 2000
    ..The mutational pattern(s) underlying both resistance and cross-resistance to PIs was investigated...
  4. pmc The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence
    H Van Marck
    Tibotec BVBA, Mechelen, Belgium
    J Virol 83:9512-20. 2009
    ..The approach elaborates on patient data and demonstrates how the specific mutational background greatly influences the impact of individual mutations on PI susceptibility in clinical patterns...